Efficacy and cost-benefit of filgrastim administered after early assessment bone marrow biopsy during induction therapy for acute myeloid leukemia

Autor:	Leland Metheny, Molly Gallogly, Kirsten M Boughan, Benjamin Tomlinson, Shufen Cao, Pingfu Fu, Jiasheng Wang, Ehsan Malek, Marcos de Lima, Paolo Caimi, Nicholas K. Schiltz, Folashade Otegbeye, Brenda W. Cooper, Brett Glotzbecker
Rok vydání:	2021
Předmět:	Oncology Cancer Research medicine.medical_specialty Filgrastim Biopsy Newly diagnosed 03 medical and health sciences 0302 clinical medicine Bone Marrow hemic and lymphatic diseases Induction therapy Internal medicine Antineoplastic Combined Chemotherapy Protocols Granulocyte Colony-Stimulating Factor medicine Humans neoplasms Retrospective Studies medicine.diagnostic_test business.industry Remission Induction Myeloid leukemia Hematology Induction Chemotherapy humanities body regions Leukemia Myeloid Acute medicine.anatomical_structure 030220 oncology & carcinogenesis Cost benefit Bone marrow business 030215 immunology medicine.drug
Zdroj:	Leukemialymphoma. 62(6)
ISSN:	1029-2403
Popis:	The role of filgrastim during acute myeloid leukemia (AML) induction therapy remains controversial. At our institution, newly diagnosed AML patients from 2003 through 2019 were retrospectively evaluated. Patients were stratified on whether they received filgrastim within 5 days after early assessment bone marrow (BMBx) and divided into early GCSF group (eGCSF) and no-eGCSF group. A total of 121 patients were included. We found significantly shorter hospital stay (median 24 vs 26 days
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::daa343e06dcd7f117cd5e5b7a3f82b3b https://pubmed.ncbi.nlm.nih.gov/33461376 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.